MedTrace Logo

18F-FDG PET in HCC Patients Candidate to Treatment With Sorafenib

NCT02977754 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2020-10-01

No results posted yet for this study

Summary

The principal objective of this study is to explore the role of 18F-FDG PET in identifying sorafenib-induced metabolic shift in HCC, thus in predicting treatment response and disease outcome in advanced HCC patients candidate to systemic treatment with sorafenib.

Conditions

Interventions

OTHER

This is an observational study

Imaging

Sponsors & Collaborators

  • Istituto Clinico Humanitas

    lead OTHER

Principal Investigators

  • Egesta Lopci · Istituto Clinico Humanitas

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-12-31
Completion
2019-03-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02977754 on ClinicalTrials.gov